Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Memantine as an augmenting agent for severe pediatric OCD.

Literature DB >> 19188297

Memantine as an augmenting agent for severe pediatric OCD.

Dianne M Hezel, Katherine Beattie, S Evelyn Stewart.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2009 PMID： 19188297 DOI： 10.1176/appi.ajp.2008.08091427

Source DB: PubMed Journal: Am J Psychiatry ISSN： 0002-953X Impact factor: 18.112

Keyword Cloud
Cited

× No keyword cloud information.

18 in total

Review 1. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors: Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal: Pharmacol Ther Date: 2011-09-22 Impact factor: 12.310

Review 2. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.

Authors: Michael H Bloch; Eric A Storch
Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-01-30 Impact factor: 8.829

Review 3. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.

Authors: Gabriele Sani; Giulia Serra; Giorgio D Kotzalidis; Silvia Romano; Stefano M Tamorri; Giovanni Manfredi; Matteo Caloro; C Ludovica Telesforo; Saverio S Caltagirone; Isabella Panaccione; Alessio Simonetti; Francesca Demontis; Gino Serra; Paolo Girardi
Journal: CNS Drugs Date: 2012-08-01 Impact factor: 5.749

Review 4. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.

Authors: Ke Wu; Gregory L Hanna; David R Rosenberg; Paul D Arnold
Journal: Pharmacol Biochem Behav Date: 2011-10-15 Impact factor: 3.533

5. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Authors: Mohammad Haghighi; Leila Jahangard; Hamid Mohammad-Beigi; Hafez Bajoghli; Hassan Hafezian; Alireza Rahimi; Hamid Afshar; Edith Holsboer-Trachsler; Serge Brand
Journal: Psychopharmacology (Berl) Date: 2013-03-23 Impact factor: 4.530

Review 6. Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors: Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal: Philos Trans R Soc Lond B Biol Sci Date: 2013-02-25 Impact factor: 6.237

Memantine as an augmenting agent for severe pediatric OCD.

Review 1. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Review 2. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.

Review 3. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.

Review 4. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.

5. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Review 6. Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

7. Glutamatergic agents for OCD and related disorders.

8. THE USE OF GLUTAMATE MODULATING DRUGS IN OBSESSIVE COMPULSIVE DISORDER.

9. Memantine: a review of possible uses in child and adolescent psychiatry.

10. Assessment and medication management of paediatric obsessive-compulsive disorder.